Blue Note Therapeutics Enters Licensing Agreement with Massachusetts General Hospital for Digital Therapeutic for Acute Myeloid Leukemia Patients

October 2020

Blue Note Therapeutics, Inc., a prescription digital therapeutics company, has entered into a licensing agreement with Massachusetts General Hospital (MGH) to further develop and commercialize a digital therapeutic prototype created specifically for patients with acute myeloid leukemia by researchers from the MGH Cancer Outcomes Research and Education Program.

A randomized head-to-head clinical trial is currently underway at MGH and Dana-Farber Cancer Institute to measure the prototype’s ability to improve the physical and psychological symptoms patients with acute myeloid leukemia experience during hospitalization for their leukemia care as compared to usual care.

For more information about the study, visit https://clinicalTrials.gov (NCT03372291).